The GF Value represents the current intrinsic value of a stock derived from our exclusive method. The GF Value Line on our summary page gives an overview of the fair value that the stock should be traded at. It is calculated based on three factors:
GuruFocus adjustment factor based on the company’s past returns and growth.
Future estimates of the business performance.
We believe the GF Value Line is the fair value that the stock should be traded at. The stock price will most likely fluctuate around the GF Value Line. If the stock price is significantly above the GF Value Line, it is overvalued and its future return is likely to be poor. On the other hand, if it is significantly below the GF Value Line, its future return will likely be higher.
Please note, "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.
As of today (2024-04-19), Regeneron Pharmaceuticals's share price is $893.50. Regeneron Pharmaceuticals's GF Value is $732.07. Therefore, Regeneron Pharmaceuticals's Price-to-GF-Value for today is 1.22.
Based on the relationship between the current stock price and the GF Value, GuruFocus believes Regeneron Pharmaceuticals is Modestly Overvalued.
Regeneron Pharmaceuticals (NAS:REGN) GF Value Explanation
Based on the relationship between the current stock price and the GF Value, GuruFocus provides the following 6 evaluations:
(1) "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.
(2) These are some simple examples. You can access our GF Valuation filter under All-in-One Screener’s Fundamental tab, and Price-to-GF-Value filter under Valuation Ratio tab and set your own criteria.
(3) There is only a sufficient margin of safety when the stock is undervalued.
Regeneron Pharmaceuticals's Price-to-GF-Value for today is calculated as
Price-to-GF-Value
=
Share Price
/
GF Value
=
893.50
/
732.07
=
1.22
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Regeneron Pharmaceuticals GF Value Related Terms
Thank you for viewing the detailed overview of Regeneron Pharmaceuticals's GF Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Regeneron Pharmaceuticals (Regeneron Pharmaceuticals) Business Description
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
REGN has been successfully added to your